166 related articles for article (PubMed ID: 34731630)
1. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
Shivange G; Mondal T; Lyerly E; Bhatnagar S; Landen CN; Reddy S; Kim J; Doan B; Riddle P; Tushir-Singh J
Cell Rep; 2021 Nov; 37(5):109953. PubMed ID: 34731630
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
3. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
[TBL] [Abstract][Full Text] [Related]
4. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
[TBL] [Abstract][Full Text] [Related]
6. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
7. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.
Weber TG; Pöschinger T; Galbán S; Rehemtulla A; Scheuer W
Neoplasia; 2013 Aug; 15(8):863-74. PubMed ID: 23908588
[TBL] [Abstract][Full Text] [Related]
10. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
[TBL] [Abstract][Full Text] [Related]
11. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.
Graves JD; Kordich JJ; Huang TH; Piasecki J; Bush TL; Sullivan T; Foltz IN; Chang W; Douangpanya H; Dang T; O'Neill JW; Mallari R; Zhao X; Branstetter DG; Rossi JM; Long AM; Huang X; Holland PM
Cancer Cell; 2014 Aug; 26(2):177-89. PubMed ID: 25043603
[TBL] [Abstract][Full Text] [Related]
12. TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
Chen JJ; Mikelis CM; Zhang Y; Gutkind JS; Zhang B
Oncotarget; 2013 Feb; 4(2):206-17. PubMed ID: 23470485
[TBL] [Abstract][Full Text] [Related]
13. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
14. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
[TBL] [Abstract][Full Text] [Related]
15. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
[TBL] [Abstract][Full Text] [Related]
16. Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment.
Sadeghnezhad G; Romão E; Bernedo-Navarro R; Massa S; Khajeh K; Muyldermans S; Hassania S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569768
[TBL] [Abstract][Full Text] [Related]
17. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.
Burvenich IJ; Lee FT; Cartwright GA; O'Keefe GJ; Makris D; Cao D; Gong S; Chueh AC; Mariadason JM; Brechbiel MW; Beckman RA; Fujiwara K; von Roemeling R; Scott AM
Clin Cancer Res; 2013 Nov; 19(21):5984-93. PubMed ID: 24045184
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
Dubuisson A; Favreau C; Fourmaux E; Lareure S; Rodrigues-Saraiva R; Pellat-Deceunynck C; El Alaoui S; Micheau O
Cell Death Dis; 2019 Feb; 10(2):101. PubMed ID: 30718507
[TBL] [Abstract][Full Text] [Related]
20. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
